Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
53 Hypertension Trials near Fort Lauderdale, FL
Power is an online platform that helps thousands of Hypertension patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerNCX 470 for Glaucoma
Fort Lauderdale, Florida
This trial is testing NCX 470 eye drops to see if they can safely and effectively lower eye pressure in people with high eye pressure or glaucoma. The goal is to protect their vision by reducing the pressure inside their eyes. NCX 470 is a nitric oxide (NO)-donating bimatoprost with clinically demonstrated pressure-lowering effects.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Narrow Angles, Ocular Disease, Surgery, Others
696 Participants Needed
Baxdrostat + Dapagliflozin for Chronic Kidney Disease and High Blood Pressure
Fort Lauderdale, Florida
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:T1DM, Uncontrolled T2DM, Heart Failure, Others
Must Be Taking:ACEi, ARB
5000 Participants Needed
Baxdrostat + Dapagliflozin for Chronic Kidney Disease
Fort Lauderdale, Florida
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN.
This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone.
Site visits will take place at 2-, 4-, 8-, and 16- weeks following randomisation. Thereafter visits will occur approximately every 4 months, until the 24-month visit at which time baxdrostat/placebo will be discontinued. Participants will continue open-label dapagliflozin for another 6-weeks (approximately), where reassessment of GFR will occur for the primary efficacy endpoint.
In the event of premature discontinuation of blinded study intervention, participants will continue in the study and receive open-label dapagliflozin monotherapy, unless the participant meets dapagliflozin specific discontinuation criteria, in which case all study interventions will be discontinued.
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Uncontrolled Diabetes, Heart Failure, Others
Must Be Taking:ACE Inhibitors, ARBs
2500 Participants Needed
Engaging Visual Field Test for Pediatric Eye Examinations
Fort Lauderdale, Florida
This trial aims to improve vision tests for young children by using a small screen with cartoon videos and voices. This approach helps keep children engaged, making the test results more reliable and aiding in better diagnosis and care for vision problems.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:5 - 8
Key Eligibility Criteria
Disqualifiers:Previous VF Test, Cognitive Impairment, Others
20 Participants Needed
Inclisiran for Cardiovascular Disease Prevention
Fort Lauderdale, Florida
This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40 - 79
Key Eligibility Criteria
Disqualifiers:ASCVD, Revascularization, Liver Disease, Others
Must Be Taking:Lipid Lowering
14013 Participants Needed
Lorundrostat for High Blood Pressure
Pembroke Pines, Florida
This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breast-feeding, Others
Must Not Be Taking:Prohibited Medications
1400 Participants Needed
QCZ484 for High Blood Pressure
Pembroke Pines, Florida
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Not Listed
380 Participants Needed
Zilebesiran for High Blood Pressure
Hollywood, Florida
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Secondary Hypertension, Orthostatic Hypotension, Others
Must Be Taking:Antihypertensives
375 Participants Needed
MANP for High Blood Pressure
Hollywood, Florida
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Secondary Hypertension, Recent MI, CHF, Others
Must Be Taking:Antihypertensives, Diuretics, ACEi Or ARB
120 Participants Needed
Lorundrostat for High Blood Pressure
Pembroke Pines, Florida
This trial tests lorundrostat, a medication that lowers blood pressure by blocking an enzyme involved in hormone production. It targets patients with high blood pressure not controlled by 2 to 5 other medications.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Age:19+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Not Listed
1083 Participants Needed
Lorundrostat for High Blood Pressure
Pembroke, Florida
This trial tests lorundrostat, a drug that lowers blood pressure by blocking a hormone that makes the body hold onto salt and water. It targets patients whose high blood pressure isn't controlled by standard treatments.
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
285 Participants Needed
Long-term Safety and Efficacy of Bimatoprost SR for Glaucoma
Tamarac, Florida
This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Other Drug Studies, Others
Must Be Taking:Bimatoprost SR
600 Participants Needed
AGN-193408 SR for Glaucoma
Tamarac, Florida
This trial is testing a new medication called AGN-193408 SR to see if it can safely lower eye pressure in people with open-angle glaucoma or ocular hypertension.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Ocular Trauma, Herpetic Ocular Diseases, Others
Must Not Be Taking:Corticosteroids
96 Participants Needed
Baxdrostat for High Blood Pressure
Hollywood, Florida
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (defined as seated SBP ≥ 140 mmHg at Screening and mean ambulatory SBP ≥ 130 mmHg at baseline, despite a stable regimen of ≥ 3 antihypertensive agents, one of which is a diuretic).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Renal Artery Stenosis, Hyperthyroidism, Hypothyroidism, Others
Must Be Taking:Antihypertensives, Diuretics
217 Participants Needed
Lorundrostat + Dapagliflozin for Kidney Disease
Hollywood, Florida
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor \[ASI\]) in addition to a SGLT2i for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an Angiotensin-converting enzyme inhibitor (ACEi) or an Angiotensin receptor blocker (ARB). Subjects will be at least 18 years old with hypertension, and mild to severe CKD with albuminuria at the Screening Visit.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Not Listed
60 Participants Needed
Orforglipron for High Blood Pressure
Boca Raton, Florida
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
487 Participants Needed
Orforglipron for High Blood Pressure
Boca Raton, Florida
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
487 Participants Needed
Orforglipron for Hypertension
Boca Raton, Florida
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Heart Failure, Stroke, Type 1 Diabetes, Others
974 Participants Needed
Bimatoprost SR for Glaucoma
Coral Springs, Florida
This trial tests a long-lasting eye medication called Bimatoprost SR. It is for people with certain eye conditions who can't use regular eye drops effectively. The medication works by helping fluid drain from the eye, reducing pressure. Bimatoprost has been widely used for glaucoma management, typically delivered via eye drops, but newer methods like sustained-release implants are being explored to improve efficiency.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Concurrent Study, Previous Bimatoprost SR
515 Participants Needed
Ralinepag for Pulmonary Arterial Hypertension
Weston, Florida
This trial is testing ralinepag, a medication being developed for the treatment of pulmonary arterial hypertension (PAH). It aims to see if adding ralinepag to their usual treatments can improve their condition. The medication works by relaxing and opening up the blood vessels in the lungs, which can lower the pressure and improve blood flow.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Severe Liver Disease, Renal Insufficiency, Malignancy, Others
Must Be Taking:Endothelin Antagonists, PDE5 Inhibitors
1000 Participants Needed
Why Other Patients Applied
"I have gasteroparesis which causes me extreme bloating, pain, acid reflux, occasional vomiting, nausea, and constipation. Most standard medications have not helped. I did some research to learn about investigational drugs, which I'd be excited to get to access through a trial."
BW
Gasteroparesis PatientAge: 38
"In December 2023 I had a stent placed in an artery. I was so glad that the blockage was found before I had either a heart attack, stroke, or both. I have been on Pravastatin for as long as I can remember but I continue to have elevated cholesterol levels. I'm trying to get ahead of my condition by learning more about the latest research and drugs available."
AQ
Hypercholesterolemia PatientAge: 57
"I have a known blockage developing in lower left main 50%, which my doctors are watching. We've considered surgery, but I'd like to rule out all possible other options first. I've done some research, which brought me to clinical trials."
PA
Artery Disease PatientAge: 64
"My ejection fraction is now 20-25%, quite low. Trying to optimize my medications at this time. I have had Biventricular pacemaker/ICD since 2007. I am doing everything I can to improve my health. Following a diet, exercising 30 minutes every day. Most days my systolic blood pressure is < 100. I had a L/R Cath in December and do not have any problems with my coronary arteries. I'm hoping to learn more about the latest research and drugs by participating in a trial. "
WB
Heart Failure PatientAge: 66
"I've been diagnosed with type 2 diabetes since 2000. I was on the highest dose of metformin, which didn't work for me. In 2022, I tried Ozempic, which had bad side effects. I'm not currently on anything to treat my diabetes, given my experiences (as well as some insurance denials). I'm glad that clinical trials exist to help me try to access the latest research. I'm frustrated but also motivated."
PL
Diabetes PatientAge: 53
High-Dose Macitentan for PAH
Weston, Florida
This trial is testing if a higher dose of macitentan can better help patients with pulmonary arterial hypertension by improving blood flow in their lungs. Macitentan has shown promise in helping patients by slowing down the disease and improving their health.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Obesity, Diabetes, Hypertension, Coronary Artery Disease, Others
935 Participants Needed
Ralinepag for Pulmonary Arterial Hypertension
Weston, Florida
This trial tests ralinepag, a medication for lung disease, on patients with PAH who participated in earlier research. It aims to improve blood flow in the lungs by relaxing blood vessels and reducing pressure.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Transplant, Others
1000 Participants Needed
Mechanical Circulatory Support for Heart Failure
Weston, Florida
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Inotrope Use, Thyroid Disease, Valvular Heart Disease, Others
Must Be Taking:Betablockers, ACE Inhibitors, Diuretics, SGLT2 Inhibitors
850 Participants Needed
Oral Ifetroban for Scleroderma
Weston, Florida
This trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Lung Disease, Kidney Disease, Others
Must Be Taking:Oral PAH Therapy
34 Participants Needed
The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Not Listed
40 Participants Needed
Virtual Reality for Stress and High Blood Pressure
Miami, Florida
The Realist Women Study wants to see if a special program using virtual reality can help Black women deal with stress and improve Black women's heart health. The study team wants to see if using virtual reality (VR) can help with stress of Black women. The investigator will look at things like sleep, stress, and how well the VR works. The investigator also wants to know about any problems Black women might have using virtual reality.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:21+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Psychosis, Vision Impairment, Epilepsy, Others
60 Participants Needed
The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other Pulmonary Hypertension Types
202 Participants Needed
Travoprost Implant for Glaucoma
Delray Beach, Florida
This trial tests a small device that releases medication inside the eye to help patients with high eye pressure due to glaucoma or ocular hypertension. The medication helps fluid drain from the eye, reducing pressure and preventing vision problems.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
105 Participants Needed
T4090 vs Rhopressa for Glaucoma
Delray Beach, Florida
The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Not Listed
126 Participants Needed
Renal Denervation for High Blood Pressure
Miami, Florida
This trial is studying the safety and effectiveness of a device called the Symplicity Spyral system, which helps lower blood pressure by calming overactive nerves in the kidneys. It includes patients who have already received this treatment. The Symplicity Spyral system is part of a series of treatments, with earlier versions showing significant blood pressure reductions in patients with resistant hypertension.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Renal Anatomy, Oxygen Support, Diabetes, Others
1400 Participants Needed
Know someone looking for new options?
Spread the word